Overview of Dr. McBride
Dr. Sean McBride is a radiation oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Yale School of Medicine and has been in practice 9 years. He is one of 106 doctors at Memorial Sloan Kettering Cancer Center and one of 26 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Radiation Oncology. He has more than 70 publications and over 500 citings.
Office
1275 York Ave
New York, NY 10065
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology, 2009 - 2013
- Harvard School of Public HealthMPH, 2011 - 2012
- California Pacific Medical CenterInternship, Internal Medicine, 2008 - 2009
- Yale School of MedicineClass of 2008
Certifications & Licensure
- FL State Medical License 2023 - Present
- NY State Medical License 2013 - 2026
- NJ State Medical License 2015 - 2019
- MA State Medical License 2011 - 2014
- American Board of Radiology Radiation Oncology
Clinical Trials
- Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer Start of enrollment: 2020 Mar 03
Roles: Contact
Publications & Presentations
PubMed
- 8 citationsLocal Failure after Prostate SBRT Predominantly Occurs in the PI-RADS 4 or 5 Dominant Intraprostatic Lesion.Daniel Gorovets, Andreas G Wibmer, Assaf Moore, Stephanie Lobaugh, Zhigang Zhang
European Urology Oncology. 2023-06-01 - 18 citationsA Multi-Institutional Phase 2 Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer.Michael R. Folkert, Michael J. Zelefsky, Raquibul Hannan, Neil Desai, Yair Lotan
International Journal of Radiation Oncology, Biology, Physics. 2021-09-01 - 4 citationsQuality Metric to Assess Adequacy of Hydrogel Rectal Spacer Placement for Prostate Radiation Therapy and Association of Metric Score With Rectal Toxicity Outcomes.Craig E Grossman, Michael R Folkert, Stephanie Lobaugh, Neil B Desai, Marisa A Kollmeier
Advances in Radiation Oncology. 2023-01-24
Lectures
- Biomarker predictors of outcome from a randomized trial of nivolumab +/- stereotactic body radiotherapy (SBRT) in metastatic (M1) head and neck squamous cell carcinoma...2019 ASCO Annual Meeting - 6/1/2019
- Baseline genomic and circulating tumor cell (CTC) correlative data from very high-risk (VHR), localized, node-negative prostate cancer patients.2019 ASCO Annual Meeting - 6/1/2019
- Apalutamide + abiraterone + leuprolide with stereotactic, ultra-hypofractionated radiation (AASUR) in very high risk prostate cancer (PCa).2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Join now to see all
Press Mentions
- New MSK Radiation Approach Means Fewer Side Effects for More Patients with HPV-Related Head and Neck CancerJanuary 20th, 2022
- ‘Contrary’ to Wide Belief, Abscopal Effect Is Rare in CancerJanuary 7th, 2021
- New SU2C Teams Accelerate Clinical Trials for Difficult Breast & Prostate CancersSeptember 16th, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: